Medtronic plc (NYSE:MDT) shares are down on Tuesday as the company announced plans to acquire Scientia Vascular, a move aimed at enhancing its neurovascular portfolio.
This decline comes as broader markets are experiencing a downturn, with major indices like the S&P 500 and Nasdaq both in the red.
$550 Million Deal
The acquisition is expected to strengthen Medtronic’s position in the neurovascular space, integrating Scientia’s access and therapeutic solutions.
The acquisition is valued at $550 million, with potential undisclosed earn-out and milestone payments post-acquisition.
Scientia is a private company with approximately 310 employees.
Deal Rationale
Under founder and current chief technology officer John Lippert, the company has developed access products that enable simplicity and access for physicians treating complex neurovascular conditions.
Scientia’s portfolio of guidewires and catheters can be integrated with Medtronic’s existing suite of neurovascular products, strengthening the company’s ability to support physicians across the full procedural workflow.
This acquisition is expected to close in the first half of fiscal 2027. It is expected to be minimally dilutive to Medtronic adjusted EPS in fiscal 2027 and accretive thereafter.
Medtronic Technical Analysis
Medtronic’s stock is currently trading 7.7% below its 20-day simple moving average (SMA) and 8.8% below its 50-day SMA, indicating a bearish trend. Over the past 12 months, shares have decreased by 4.25% and are positioned closer to their 52-week lows than highs.
The RSI is at 29.66, which is considered oversold territory, suggesting potential for a rebound if buying pressure increases. Meanwhile, the MACD is at -1.8676, below its signal line at -1.1145, indicating bearish momentum.
The combination of oversold RSI and bearish MACD suggests mixed momentum, reflecting uncertainty in the stock’s near-term outlook.
- Key Resistance: $106.00
- Key Support: $88.00
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $109.82. Recent analyst moves include:
- JP Morgan: Neutral (Lowers Target to $100.00) (Feb. 18)
- Barclays: Overweight (Raises Target to $118.00) (Feb. 18)
- Baird: Neutral (Lowers Target to $100.00) (Feb. 18)
Medtronic Benzinga Edge Rankings
Below is the Benzinga Edge scorecard for Medtronic plc, highlighting its strengths and weaknesses compared to the broader market:
- Value Rank: 25 — The stock is trading at a steep premium relative to peers.
- Quality Rank: 38.1 — Balance sheet remains healthy.
- Momentum Rank: 26.07 — Stock is underperforming the broader market.
The Verdict: Medtronic plc’s Benzinga Edge signal reveals a mixed outlook. While the Quality score indicates a solid balance sheet, the low Value and Momentum scores suggest that the stock is currently struggling in the market.
Medtronic’s Top ETF Exposure
- Cullen Enhanced Equity Income ETF (NYSE:DIVP): 4.25% Weight
- Strategas Macro Momentum ETF (NYSE:SAMM): 3.98% Weight
- Eventide Large Cap Value ETF (NYSE:ESLV): 2.12% Weight
MDT Price Action: Medtronic shares were down 1.07% at $90.36 at the time of publication on Tuesday, according to Benzinga Pro data.
Image via Shutterstock
This article Medtronic's $550 Million Scientia Vascular Deal Aims To Boost Neurovascular Portfolio originally appeared on Benzinga.com
.
